Clinical trial
Three Doses of TAS-108 to Treat Recurrent or Recurrent Inoperable Breast Cancer
NCT00166543 · SRI International, Industry · Completed
Key facts
| NCT number | NCT00166543 |
|---|---|
| Title | Three Doses of TAS-108 to Treat Recurrent or Recurrent Inoperable Breast Cancer |
| Official title | A Phase II, Randomized, Double-Blinded Efficacy and Safety Study of Three Doses of TAS-108 Administered Orally in Postmenopausal Patients With Locally Advanced or Locally Recurrent Inoperable or Progressive Metastatic Breast Cancer Following Standard First-Line Endocrine Therapy |
| Lead sponsor | SRI International, Industry |
| Collaborators | Taiho Pharmaceutical Co., Ltd. Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Breast Cancer |
| Intervention type | Drug |
| Interventions | TAS-108 |
| Enrollment | 146 |
| Start date | May 1, 2004 |
| Primary completion | Jan 1, 2008 |
| Completion | Jan 1, 2008 |
| First posted | Sep 14, 2005 |
| Last update posted | Aug 18, 2015 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: